FMBA of Russia has patented a domestic product from COVID-19

Federal medical-biological Agency (FMBA) of Russia has patented a domestic drug for the treatment of coronavirus infection. According to a release on the Agency’s website, the drug is able to prevent or mitigate the cytokine storm (inflammatory response when the immune system attacks cells and tissues of the body — approx. ed.). In FMBA noted that “Beitragen” — a purely domestic product. As explained in the Agency, the common name of the source of the drug “dalargin”, it was previously used for the treatment of stomach ulcers, acute pancreatitis and pancreatic necrosis. However, Russian scientists have found that this medicine plays an active role in the processes of healing and tissue regeneration. In addition, substances of this class are actively involved in the organization of the immune response, otmetili in FMBA. In the end, the researchers, given these properties “dalargin”, used it to create new formulations against coronaviruses. The development was named “beitragen”. The Agency indicated that the most effective way of applying new dosage forms — inhalation. Rospatent has already taken a decision on the grant of a patent, nowadays the registration document.